Literature DB >> 32488481

Commentary: The Multiple Sclerosis Controversy: Is It Escalation or Induction High Efficacy?

Patricia K Coyle1.   

Abstract

Mesh:

Substances:

Year:  2020        PMID: 32488481      PMCID: PMC7609745          DOI: 10.1007/s13311-020-00869-8

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


× No keyword cloud information.
  6 in total

1.  [Evaluation of reinductions in a modern protocol for the treatment of childhood acute lymphoblastic leukaemias. Analysis of the D-74 protocol (author's transl)].

Authors:  J J Ortega; G Javier
Journal:  Sangre (Barc)       Date:  1981

2.  Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.

Authors:  Katharine Harding; Owain Williams; Mark Willis; James Hrastelj; Anthony Rimmer; Fady Joseph; Valentina Tomassini; Mark Wardle; Trevor Pickersgill; Neil Robertson; Emma Tallantyre
Journal:  JAMA Neurol       Date:  2019-05-01       Impact factor: 18.302

3.  Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.

Authors:  Anna He; Bernd Merkel; James William L Brown; Lana Zhovits Ryerson; Ilya Kister; Charles B Malpas; Sifat Sharmin; Dana Horakova; Eva Kubala Havrdova; Tim Spelman; Guillermo Izquierdo; Sara Eichau; Maria Trojano; Alessandra Lugaresi; Raymond Hupperts; Patrizia Sola; Diana Ferraro; Jan Lycke; Francois Grand'Maison; Alexandre Prat; Marc Girard; Pierre Duquette; Catherine Larochelle; Anders Svenningsson; Thor Petersen; Pierre Grammond; Franco Granella; Vincent Van Pesch; Roberto Bergamaschi; Christopher McGuigan; Alasdair Coles; Jan Hillert; Fredrik Piehl; Helmut Butzkueven; Tomas Kalincik
Journal:  Lancet Neurol       Date:  2020-03-18       Impact factor: 44.182

Review 4.  Immune reconstitution therapies: concepts for durable remission in multiple sclerosis.

Authors:  Jan D Lünemann; Heinz Wiendl; Tobias Ruck; Paolo A Muraro; Amit Bar-Or
Journal:  Nat Rev Neurol       Date:  2019-10-24       Impact factor: 42.937

5.  Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.

Authors:  J William L Brown; Alasdair Coles; Dana Horakova; Eva Havrdova; Guillermo Izquierdo; Alexandre Prat; Marc Girard; Pierre Duquette; Maria Trojano; Alessandra Lugaresi; Roberto Bergamaschi; Pierre Grammond; Raed Alroughani; Raymond Hupperts; Pamela McCombe; Vincent Van Pesch; Patrizia Sola; Diana Ferraro; Francois Grand'Maison; Murat Terzi; Jeannette Lechner-Scott; Schlomo Flechter; Mark Slee; Vahid Shaygannejad; Eugenio Pucci; Franco Granella; Vilija Jokubaitis; Mark Willis; Claire Rice; Neil Scolding; Alastair Wilkins; Owen R Pearson; Tjalf Ziemssen; Michael Hutchinson; Katharine Harding; Joanne Jones; Christopher McGuigan; Helmut Butzkueven; Tomas Kalincik; Neil Robertson
Journal:  JAMA       Date:  2019-01-15       Impact factor: 56.272

Review 6.  Optimizing treatment success in multiple sclerosis.

Authors:  Tjalf Ziemssen; Tobias Derfuss; Nicola de Stefano; Gavin Giovannoni; Filipe Palavra; Davorka Tomic; Tim Vollmer; Sven Schippling
Journal:  J Neurol       Date:  2015-12-24       Impact factor: 4.849

  6 in total
  1 in total

Review 1.  Escalation vs. Early Intense Therapy in Multiple Sclerosis.

Authors:  Bonaventura Casanova; Carlos Quintanilla-Bordás; Francisco Gascón
Journal:  J Pers Med       Date:  2022-01-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.